💉 the Oxford jab is far cheaper and easier to store than Pfizer and Moderna’s
💉 the UK has pre-ordered 100m doses
💉 the 90% success rate comes when people were given a ‘low’ dose, followed by a ‘high’ one - which should mean there’s more vaccine to go around.
💉 the UK has pre-ordered 100m doses
💉 the 90% success rate comes when people were given a ‘low’ dose, followed by a ‘high’ one - which should mean there’s more vaccine to go around.
https://twitter.com/uniofoxford/status/1330769567409385474
Health Secretary Matt Hancock tells @LBC its “good news and a good day.”
Next the regulator needs to look at this data and “will only sign it off if it’s safe.”
Then “the NHS stands ready to deliver the Pfizer and Oxford vaccines from next month.”
Next the regulator needs to look at this data and “will only sign it off if it’s safe.”
Then “the NHS stands ready to deliver the Pfizer and Oxford vaccines from next month.”
Matt Hancock tells @LBC he should be in one of the first waves to get the coronavirus vaccine as “I count technically as a health worker, as the Health Secretary.”
He says he’s very happy to get the jab if the regulator finds it’s safe.
He says he’s very happy to get the jab if the regulator finds it’s safe.
Prof Sarah Gilbert from Uni of Oxford suggested the (slightly confusing perhaps) reason their vaccine seems to work better with less dosage, is that it is 'mimicking what happens in a real infection' and then kicking the immune system into action.
Oxford scientists says it looks like their vaccine limited asymptomatic transmission and stopped their volunteers from getting a 'severe' hit of the disease. So it looks like it should limit both hospitalisations and transmission. That would be huge.
Pam Cheng from AstraZeneca says they have been working with over 20 supply chain partners around the world, and hope to make up to 3 billion doses of the vaccine in 2021.
They're aiming for 'broad and equitable supply' with a 'non-competing supply chain.' @LBC
They're aiming for 'broad and equitable supply' with a 'non-competing supply chain.' @LBC
More good news! Oxford/AstraZenica press conference reveals that the half-dose/full-dose vaccine rollout is 'even better tolerated' in limiting side effects.
Those side effects are limited and normal for vaccines - so sore arm, some people with headaches and feeling tired.
Those side effects are limited and normal for vaccines - so sore arm, some people with headaches and feeling tired.
Prof Sarah Gilbert says they didn't just think about the immune response before starting to make this vaccine, but also how easily it can be administered. A benefit of the Oxford jab is that it can be stored in a fridge.
To explain fully, because some people are happy to tweet first, read details never:
70% was the average success rate based on the whole study.
That rose to 90% efficacy in a sub-study which adjusted (shrank) the dosage.
70% was the average success rate based on the whole study.
That rose to 90% efficacy in a sub-study which adjusted (shrank) the dosage.
Just compare the costs -
💷 Oxford vaccine is priced at around £3
💷 Pfizer’s vaccine around £15
💷 Moderna’s at £25
inews.co.uk/news/analysis/…
💷 Oxford vaccine is priced at around £3
💷 Pfizer’s vaccine around £15
💷 Moderna’s at £25
inews.co.uk/news/analysis/…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
